SCHEMBL29300366

SCHEMBL29300366

CC(C)CCCCNC(=O)CCNC(=O)[C@@H](N)CCC(=O)NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP7 Q9UHL4 2/20 0.39
▸ GNAI3 P08754 1/20 0.38
▸ GNAO1 P09471 1/20 0.38
▸ GNAI1 P63096 1/20 0.38
▸ NOD1 Q9Y239 1/20 0.38
▸ RRM1 P23921 1/20 0.37
▸ ANPEP P15144 3/20 0.35
▸ DNPEP Q9ULA0 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NMT2 O60551 1/20 0.34
▸ NMT1 P30419 1/20 0.34
▸ TERT O14746 2/20 0.33
▸ LTA4H P09960 1/20 0.32
▸ GPBAR1 Q8TDU6 1/20 0.32
▸ FNTA P49354 2/20 0.31
▸ FNTB P49356 2/20 0.31
▸ PGGT1B P53609 1/20 0.31
▸ RNPEP Q9H4A4 2/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ NAAA Q02083 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29299807 0.89 ALDH1A1 (0.36) ANPEPDNPEPALDH1A1NMT2NMT1
SCHEMBL29300253 0.86 NMT2 (0.35) ALDH1A1NMT2NMT1GPBAR1KDM4E
SCHEMBL29300207 0.85 NMT2 (0.35) ALDH1A1NMT2NMT1GPBAR1
SCHEMBL27333270 0.82 USP2 (0.40) DPP7NOD1ALDH1A1LTA4HGPBAR1
SCHEMBL20223256 0.82 USP2 (0.40) DPP7NOD1ALDH1A1LTA4HGPBAR1
SCHEMBL9011923 0.78 MEN1 (0.42) ALDH1A1NMT2NMT1GPBAR1KDM4E
SCHEMBL22738631 0.78 KDM4E (0.46) ALDH1A1GPBAR1KDM4E
SCHEMBL29300141 0.77 GLP1R (0.33) ALDH1A1NMT2NMT1GPBAR1
SCHEMBL29301977 0.76 FOLH1 (0.43) —
SCHEMBL29299844 0.76 GLP1R (0.38) NOD1ALDH1A1NMT2NMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R DPP7 1196/4885GNAI3 1655/4885GNAO1 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback